Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide plus R-CHOP vs placebo plus R-CHOP in previously untreated ABC-type DLBCL
CTR20160088Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), sponsored by Celgene Corporation. Started Mar 2016; status: completed.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20160088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160088.